Pharmaceutical News

RSS

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.

31 Jan 2012

Bioton and Actavis form joint venture

Actavis and Bioton announced today that they have formed a joint venture company for the development and registration of insulins, including analogue insulins.

31 Jan 2012

Indoco, DSM sign agreement for commercial cooperation for eight APIs

Royal DSM N.V., today announced the signing of an agreement with Indoco Remedies Limited, Mumbai, India, for commercial cooperation for eight Active Pharmaceutical Ingredients (APIs). The alliance came into effect in January 2012.

31 Jan 2012

Takeda returns POSIDUR development and commercialization rights to DURECT

DURECT Corporation today reported that Takeda has given notice that it is returning its development and commercialization rights to POSIDUR in Europe and their other licensed territories.

31 Jan 2012

CDC models show scaling up ART for HIV treatment can save money over time

During a webinar Thursday hosted by the Health Global Access Project, AVAC, and amfAR, John Blandford, chief of CDC's Division of Global HIV/AIDS Health Economics, Systems and Integration Branch, presented findings showing "that scaling up antiretroviral therapy (ART) for HIV/AIDS treatment and prevention in the developing world not only saves lives, but saves money too," the Center for Global Health Policy's "Science Speaks" blog reports.

31 Jan 2012

Neutra closer to delivering Pure Plus weight-loss supplement

Neutra Corp., an emerging provider of innovative nutraceuticals, announced today that it is one step closer to delivering its revolutionary Pure Plus weight-loss supplement to market.

31 Jan 2012

FDA approves Genentech's Erivedge for treatment of BCC

Genentech, a member of the Roche Group, today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

31 Jan 2012

Genentech receives FDA approval for Erivedge to treat basal cell carcinoma

Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body.

31 Jan 2012

Watson plans to establish Global R&D Technology Center in North Brunswick

Watson Pharmaceuticals, Inc. today announced plans to establish a Global R&D Technology Center in North Brunswick, New Jersey.

30 Jan 2012

FDA approves Baxter's TISSEEL for general hemostasis in surgery

Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved TISSEEL [Fibrin Sealant] to include general hemostasis in surgery when control of bleeding by standard surgical techniques is ineffective or impractical.

From Baxter International Inc. 30 Jan 2012

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.

30 Jan 2012

Gilenya prevents and reverses symptoms of ventricular hypertrophy

A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found.

30 Jan 2012

FDA approves Lannett's ANDA for Hydrochlorothiazide Capsules, 12.5 mg

Lannett Company, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrochlorothiazide Capsules, 12.5 mg.

30 Jan 2012

Cell Therapeutics voluntarily withdraws Pixuvri NDA for NHL

Cell Therapeutics, Inc. announced today that it has voluntarily withdrawn its New Drug Application for Pixuvri (pixantrone) for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed two or more lines of prior therapy.

30 Jan 2012

Inlyta receives FDA approval for treatment of advanced kidney cancer

The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.

30 Jan 2012

FTC terms Omnicare's proposed acquisition of PharMerica illegal

The Federal Trade Commission issued a complaint to block Omnicare, Inc.'s hostile acquisition of rival long-term care pharmacy provider PharMerica Corporation, alleging that the combination of the two largest U.S. long-term care pharmacies would harm competition and enable Omnicare to raise the price of drugs for Medicare Part D consumers and others.

30 Jan 2012

Scientists develop new vaccine to treat cancer at pre-clinical level

Scientists in Trinity College Dublin, Ireland, have developed a new vaccine to treat cancer at the pre-clinical level. The research team led by Professor Kingston Mills, Professor of Experimental Immunology at Trinity College Dublin discovered a new approach for treating the disease based on manipulating the immune response to malignant tumours.

27 Jan 2012

New discovery paves way for genetic screening test

Researchers at the Columbia University College of Dental Medicine have identified a genetic variation that raises the risk of developing serious necrotic jaw bone lesions in patients who take bisphosphonates, a common class of osteoclastic inhibitors.

27 Jan 2012

DWH signs collaboration agreement with CPDD

Developing World Health (DWH), a leading medical charity based in Stirlingshire, Scotland and committed to developing effective treatments for neglected tropical diseases, has signed a collaboration agreement with the internationally respected Consortium for Parasitic Drug Development (CPDD), based at The University of North Carolina at Chapel Hill.

27 Jan 2012

Rapid discontinuation of prednisone after kidney transplant can help prevent side effects

Rapid discontinuation of the immunosuppressive steroid prednisone after a kidney transplant can help prevent serious side effects, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

27 Jan 2012